Recombinant monoclonal antibody to CD22. Manufactured using Recombinant Platform with variable regions (i.e. specificity) from the hybridoma hL22 (Epratuzumab).
应用类型
抗CD22（依普妥珠单抗），人类IgG1抗体Anti-CD22 (Epratuzumab), Human IgG1 Antibody该产品的应用类型查阅产品说明书。
免疫原
This antibody was prepared by the humanization of LL2 (EPB-2), a murine anti-CD22 IgG2a raised against Raji Burkitt lymphoma cells. Murine sequences comprise 5–10% of the molecule, with the remainder being human framework sequences, which greatly reduces the potential for immunogenicity (Traczewski, 2010).
来源宿主
提供的抗CD22（依普妥珠单抗），人类IgG1抗体Anti-CD22 (Epratuzumab), Human IgG1 Antibody产品，该来源宿主查看产品说明书。
